Abstract
Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Current Drug Targets
Title: Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
Volume: 10 Issue: 2
Author(s): U. Elsasser-Beile, P. Buhler and P. Wolf
Affiliation:
Keywords: Prostate specific membrane antigen, prostate cancer, immunotherapy, drug targeting, radiotherapy, gene therapy
Abstract: Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and firstgeneration products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.
Export Options
About this article
Cite this article as:
Elsasser-Beile U., Buhler P. and Wolf P., Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354601
DOI https://dx.doi.org/10.2174/138945009787354601 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Docking, Antioxidant, Anticancer and Antileishmanial Effects of Newly Synthesized Quinoline Derivatives
Anti-Cancer Agents in Medicinal Chemistry HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases
Mini-Reviews in Medicinal Chemistry Resveratrol Promotes HIV-1 Tat Accumulation <i>via</i> AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency
Current HIV Research Interaction between Gastric and Upper Small Intestinal Hormones in the Regulation of Hunger and Satiety: Ghrelin and Cholecystokinin Take the Central Stage
Current Protein & Peptide Science <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Synthesis, Anticancer Screening and Molecular Docking Studies of New Heterocycles with Trimethoxyphenyl Scaffold as Combretastatin Analogues
Mini-Reviews in Medicinal Chemistry Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets